Wegovy vs Zepbound: Which Weight Loss Injection Produces Better Results?
| Category | Wegovy | Zepbound |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Drug Class | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| FDA-Approved Indication | Chronic weight management; cardiovascular risk reduction in obesity/overweight | Chronic weight management |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Approval Year | 2021 | 2023 |
| Maximum Dose | 2.4 mg once weekly | 15 mg once weekly |
| Titration to Max Dose | 16 weeks (5 dose steps) | 20 weeks (6 dose steps) |
| Mean Weight Loss (Key Trial) | 14.9% (STEP 1, 68 weeks) | 22.5% (SURMOUNT-1, 72 weeks, 15 mg) |
| Patients Losing ≥20% Body Weight | 32% (STEP 1) | 36% at 15 mg (SURMOUNT-1) |
| Patients Losing ≥5% Body Weight | 86.4% (STEP 1) | 91% at 15 mg (SURMOUNT-1) |
| Cardiovascular Outcomes | SELECT trial: 20% MACE reduction (FDA-approved indication) | No completed cardiovascular outcomes trial |
| Nausea Rate | 44% (at 2.4 mg in STEP 1) | 24-33% (dose-dependent in SURMOUNT-1) |
| Discontinuation Rate (Adverse Events) | 7% (STEP 1) | 4.3-7.1% (dose-dependent, SURMOUNT-1) |
| Cost (Without Insurance) | ~$1,349/month | ~$1,059/month (pen); $399-$549/month (vials, cash-pay) |
| Pen Type | Single-dose pre-filled pens | Single-dose pre-filled pens; also available as vials |
Wegovy vs Zepbound: The Weight Management Showdown
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the two FDA-approved injectable medications specifically indicated for chronic weight management in adults with obesity or overweight. They represent the current standard of care for pharmacological weight loss. Wegovy was approved first (June 2021) and has the advantage of longer real-world experience, completed cardiovascular outcomes data (SELECT trial), and adolescent approval. Zepbound (approved November 2023) has produced greater average weight loss in clinical trials, reflecting its dual GLP-1/GIP mechanism. Both are once-weekly subcutaneous injections with similar titration protocols and GI side effect profiles. The choice between them often comes down to insurance coverage, cost, and individual response.
STEP vs SURMOUNT: Comparing the Clinical Evidence
The STEP trial program (Wegovy) and the SURMOUNT program (Zepbound) are the pivotal clinical trials supporting each drug's approval for weight management. In STEP 1, participants without diabetes lost an average of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg, with 32% achieving 20% or more weight loss. In SURMOUNT-1, participants lost 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg tirzepatide doses respectively over 72 weeks, with over one-third of the 15 mg group losing 20% or more. The STEP 5 trial demonstrated semaglutide's 2-year durability (15.2% sustained loss). SURMOUNT-4 showed that participants maintaining tirzepatide for 88 weeks held 21.4% loss, while those switched to placebo regained significantly. Cross-trial comparisons suggest Zepbound produces approximately 50% more weight loss than Wegovy on average, but individual responses vary.
The Cardiovascular Advantage: Wegovy's SELECT Data
Wegovy holds a significant advantage in cardiovascular outcomes evidence. The SELECT trial enrolled 17,604 overweight or obese adults with established cardiovascular disease (but without diabetes) and showed that semaglutide 2.4 mg reduced the combined risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% over a mean follow-up of 39.8 months. This led to the FDA granting Wegovy a cardiovascular risk reduction indication in March 2024 — a distinction Zepbound does not have. For patients whose primary treatment goal is cardiovascular risk reduction in addition to weight loss, this evidence tips the balance toward Wegovy. Eli Lilly's cardiovascular outcomes trial for tirzepatide (SURPASS-CVOT) is underway but not yet completed.
Cost and Access: Where Zepbound Has an Edge
In terms of cost, Zepbound has a notable advantage. Wegovy's list price is approximately $1,349 per month, while Zepbound's pen price is approximately $1,059 per month. More significantly, Eli Lilly has introduced Zepbound single-dose vials at $399 per month (2.5 mg) and $549 per month (5 mg) for cash-pay patients — roughly one-third the cost of Wegovy. Insurance coverage for both remains variable, with many plans now covering at least one anti-obesity medication. Manufacturer savings programs from both companies can reduce costs to as low as $25 per month for eligible commercially insured patients. For uninsured or underinsured patients, the Zepbound vial pricing makes tirzepatide substantially more accessible than Wegovy.
- Wegovy list price: ~$1,349/month
- Zepbound pen price: ~$1,059/month
- Zepbound vials (cash-pay): $399/month (2.5 mg) or $549/month (5 mg)
- Both offer manufacturer copay cards: as low as $25/month for commercially insured
- Insurance coverage varies — check both before choosing
- Zepbound vials are the most affordable brand-name GLP-1 option for cash-pay patients
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.
Frequently Asked Questions
Based on cross-trial comparisons, Zepbound (tirzepatide) produces approximately 50% greater average weight loss than Wegovy (semaglutide): 22.5% vs 14.9% in the largest trials. However, no direct head-to-head trial has compared these specific products at their full weight-management doses. Individual responses vary significantly — some patients achieve excellent results with Wegovy and may not need to switch. The dual GLP-1/GIP mechanism of tirzepatide is believed to account for the greater average efficacy.
Side effect profiles are similar, but nausea rates appear somewhat lower with Zepbound. In SURMOUNT-1, nausea rates were 24-33% for tirzepatide (dose-dependent) compared to 44% for semaglutide 2.4 mg in STEP 1. Discontinuation rates due to adverse events were comparable. Both medications cause primarily GI symptoms that typically improve during the first 4-8 weeks of each dose level. Cross-trial comparisons of side effects should be interpreted cautiously.
Zepbound is less expensive at list price (~$1,059/month vs ~$1,349/month for Wegovy). The biggest difference is the Zepbound vial option at $399-$549/month for cash-pay patients, which has no equivalent for Wegovy. With commercial insurance and manufacturer copay cards, both can cost as little as $25/month. Your actual cost depends on your specific insurance plan, so compare both options before deciding.
Yes. Wegovy has three notable advantages: (1) completed cardiovascular outcomes data from the SELECT trial showing 20% MACE reduction, which led to an FDA cardiovascular risk reduction indication; (2) longer real-world experience and safety data (approved 2 years earlier); and (3) FDA approval for adolescents aged 12 and older (STEP TEENS trial). For patients with established cardiovascular disease, Wegovy's proven cardiovascular benefit is a meaningful differentiator.
Yes, switching between Wegovy and Zepbound is possible and does not require a washout period. When switching, most prescribers start the new medication at the lowest initiation dose (0.25 mg for Wegovy or 2.5 mg for Zepbound) since the two drugs have different mechanisms and potency profiles. GI side effects may recur during the transition. A new prior authorization from your insurer is typically required.